Reynders McVeigh Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Reynders McVeigh Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.4M	Buy	54,664 +759	+1%	+$354K	1.23%	29
2025 Q4	$24.4M	Sell	53,905 -1,445	-3%	-$623K	1.15%	28
2025 Q3	$21.7M	Buy	55,350 +1,040	+2%	+$435K	1.02%	34
2025 Q2	$24.2M	Buy	54,310 +974	+2%	+$449K	1.21%	32
2025 Q1	$25.9M	Buy	53,336 +1,082	+2%	+$504K	1.44%	30
2024 Q4	$21M	Buy	52,254 +3,524	+7%	+$1.63M	1.11%	34
2024 Q3	$22.7M	Buy	48,730 +6,269	+15%	+$3.01M	1.2%	32
2024 Q2	$19.9M	Buy	42,461 +11,860	+39%	+$5.15M	1.13%	31
2024 Q1	$12.8M	Buy	30,601 +14,460	+90%	+$6.11M	0.74%	41
2023 Q4	$6.57M	Buy	16,141 +2,070	+15%	+$765K	0.42%	47
2023 Q3	$4.89M	Buy	14,071 +4,689	+50%	+$1.64M	0.34%	50
2023 Q2	$3.3M	Buy	9,382 +5,410	+136%	+$1.82M	0.22%	57
2023 Q1	$1.25M	Buy	3,972 +2,547	+179%	+$764K	0.09%	83
2022 Q4	$412K	Buy	+1,425	New	+$434K	0.03%	152

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Reynders McVeigh Capital Management's VRTX Position: Q1 2026 in Review

Reynders McVeigh Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q1 2026, buying an estimated $354K and bringing the position to 54,664 shares worth $24.4M. The position accounts for 1.23% of the portfolio, ranked #29.

Reynders McVeigh Capital Management first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $25.9M in Q1 2025. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Reynders McVeigh Capital Management held 54,664 shares of Vertex Pharmaceuticals worth $24.4M as of Q1 2026.
Reynders McVeigh Capital Management bought 759 Vertex Pharmaceuticals shares in Q1 2026, an estimated $354K.
Vertex Pharmaceuticals made up 1.23% of Reynders McVeigh Capital Management's portfolio in Q1 2026, its #29 holding.
Reynders McVeigh Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
Reynders McVeigh Capital Management's Vertex Pharmaceuticals position peaked at $25.9M in Q1 2025.
1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.